Developing new drugs and vaccines for cancer treatment
TO Title: Contract Orientation & Kickoff Meeting for Preclinical Services for PREVENTBase IDIQ Title: PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate End
This study is all about finding new drugs and vaccines to help fight cancer, and it’s designed to make sure these treatments are safe and effective before they’re tested on people, which could lead to better options for patients like you.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11020345 on NIH RePORTER |
What this research studies
This research focuses on the PREVENT Cancer Preclinical Drug Development Program, which aims to create a systematic process for developing new drugs and vaccines for cancer. It involves evaluating the effectiveness of these treatments before they are tested in humans, using preclinical models to gather data on their efficacy and safety. Patients may benefit from this research as it seeks to advance innovative therapies that could improve cancer treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with various types of cancer who are interested in new treatment options.
Not a fit: Patients with non-malignant conditions or those who are not currently diagnosed with cancer may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of more effective cancer treatments and vaccines.
How similar studies have performed: Previous research in preclinical drug development has shown promise in advancing cancer therapies, indicating that this approach has potential for success.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Vilar Sanchez, Eduardo — University of Tx Md Anderson Can Ctr
- Study coordinator: Vilar Sanchez, Eduardo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.